Summary of AVITA Medical FY Conference Call Company Overview - **Company**: AVITA Medical (NasdaqCM:RCEL) - **Industry**: Acute wound care, specifically focused on hospital-based treatments for burns, surgical wounds, and traumatic wounds [2][3] Core Products - **RECELL**: Flagship product for acute wound care, evolving from a manual to an automated process (RECELL GO and RECELL GO mini) [4][5] - **Cohealyx**: Collagen dermal matrix that prepares the wound bed for grafting, offering quicker vascularization compared to competitors [5][6] - **PermeaDerm**: Temporary biosynthetic matrix that protects and allows observation of the wound during healing [6][7] Market Dynamics - **Target Market**: Approximately 200 accounts in the U.S. with a Total Addressable Market (TAM) of $3.5 billion, focusing on a strategic TAM of $1.3 billion [11] - **Market Penetration**: Currently less than 5% across the portfolio, with RECELL at about 15% penetration [11][12] - **International Expansion**: Efforts in Australia, Japan, and Europe, with recent attention due to a Swiss nightclub fire highlighting the need for better treatment options [12][13] Financial Performance - **Growth Rate**: Achieved 11% growth in the previous year despite challenges, with expectations for sequential growth throughout 2026 [14][15] - **CAGR**: Company has experienced a compound annual growth rate of close to 30% over the last five years [14] - **Cost Management**: Focus on cost discipline while aiming for revenue growth, with strategic reductions in the sales force [15][16] Reimbursement Challenges - **Reimbursement Dynamics**: Ongoing issues with reimbursement from CMS and MACs, with about 70%-80% recovery expected in the near term [30][35] - **Impact on Sales**: Delays in reimbursement have caused confusion and disruption, but clarity is expected to improve in the coming months [33][34] Strategic Focus - **Product Adoption**: Emphasis on increasing penetration in existing accounts and expanding usage among different types of wounds and physicians [40][61] - **Clinical Studies**: Ongoing post-market studies for Cohealyx and PermeaDerm, with results expected to support product adoption [7][13] - **Sales Strategy**: A clinically based sales team that acts as consultants to surgeons, enhancing familiarity with products [62][63] Economic Benefits - **Speed to Healing**: RECELL allows patients to heal and be discharged 36% sooner, providing economic advantages for hospitals [53][72] - **Cost Savings**: Transitioning from allograft to PermeaDerm can save hospitals significant costs, as highlighted by a physician's estimate of $500,000 in annual savings [87] Profitability Outlook - **Margin Expectations**: Cohealyx and PermeaDerm expected to have around 50% margins, while RECELL will maintain higher margins in the low 80s [92] - **Path to Profitability**: Anticipated growth trajectory suggests that profitability is on the horizon if current trends continue [93] Conclusion - **Future Outlook**: AVITA Medical is positioned for growth with a strong focus on execution and product adoption, expecting to discuss improved financial metrics throughout the year [97]

Tandem Diabetes Care FY Conference Summary Company Overview - **Company**: Tandem Diabetes Care (NasdaqGM:TNDM) - **Date of Conference**: March 04, 2026 Key Points Industry and Market Dynamics - The diabetes care market has evolved, with a shift from simple device outcomes to include market access and form factor as competitive elements [5][6] - The introduction of new competitive devices has changed the basis of competition in the industry [5] Strategic Initiatives - **2024 Strategy**: Focus on monetization of the sales force, innovative products, and market access through the pharmacy channel [6] - **Sales Force Expansion**: Increased sales force productivity through new models and a new CRM system [6][7] - **Direct Market Access**: Initiated direct sales in three new countries in 2025, with plans to expand to three more in 2027 [7][8] Product Innovations - **Control-IQ+**: Launched in 2025, designed to be user-friendly and competitive in the market [8] - **FreeStyle Libre 3 Integration**: Enhanced compatibility with t:slim, targeting the 60% of U.S. users on iOS [9] - **Mobi Development**: Ongoing enhancements to Mobi, with Android compatibility added [9] Pharmacy Channel Strategy - **PAYGO Model**: Transitioning to a pay-as-you-go model, expected to double reimbursement over a four-year product life [14][19] - **Market Positioning**: Anticipated monthly cost of $350 per patient under PAYGO, compared to $83 through traditional DME [21][22] - **Competitive Advantage**: Established install base allows for quicker conversion to pharmacy channel compared to smaller competitors [23] Financial Projections - **Growth Expectations**: Projecting 10%-11% growth in pumps shipped, with over half expected to come from renewals [57][58] - **Cost Structure**: Anticipated gross margins of 65% and operating margins of 25% as the business model shifts [132] Future Product Pipeline - **Mobi Tubeless**: Expected to be a game changer with extended wear capabilities and improved user experience [97][100] - **Closed Loop Algorithm**: Development of a fully closed loop system, with clinical studies planned for 2026 [108][109] Challenges and Considerations - **Patient Transition**: Educating existing patients on the new pharmacy model and ensuring they understand the benefits [41][49] - **Contracting Process**: Building relationships with pharmacy benefit managers (PBMs) and navigating the contracting landscape [86][90] Conclusion - Tandem Diabetes Care is positioned for significant growth through innovative product offerings and a strategic shift to a pharmacy-based model, with expectations of improved profitability and market share in the diabetes care industry [132]

超研股份于2025年1月22日在深交所创业板上市，公开发行总股数为6,424.9446万股，发行价格为6.70 元/股，保荐机构为中国银河（601881）证券股份有限公司，保荐代表人为张悦、王飞。 超研股份首次公开发行募集资金总额为43,047.13万元，扣除发行费用后募集资金净额38,436.32万元，该 公司募集资金净额比原计划多7,290.57万元。超研股份于2025年1月17日披露的招股说明书显示，该公司 拟募资31,145.75万元，用于"医用成像产品研发及产业化建设项目""工业无损检测系统研发项目""便携 式DR系统研发、产业化及市场建设项目""创新基地建设项目"。 中国经济网北京3月4日讯超研股份（301602）(301602.SZ)今日盘中最低报20.20元，创上市以来股价新 低。截至今日收盘，超研股份报20.30元，跌幅2.17%，总市值86.95亿元。 超研股份公开发行新股的发行费用合计4,610.81万元(不含增值税)，其中保荐及承销费用2,978.10万元。 ...

Financial Data and Key Metrics Changes - NeuroPace reported Q4 2025 revenue of $26.6 million, a 24% year-over-year increase from $21.5 million in Q4 2024 [4][17] - RNS System revenue was $22.4 million, reflecting a 26% year-over-year growth [4][17] - Gross margin improved to 77.4%, up from 75.4% in Q4 2024, driven by higher margin RNS revenue and manufacturing efficiencies [18] - Adjusted EBITDA was positive at $900,000, marking a $1.9 million improvement year-over-year [22] - For the full year 2025, total revenue grew 25% to $100 million, with RNS System sales also increasing by 25% [24] Business Line Data and Key Metrics Changes - The core RNS business continues to show strong growth, with a 29% increase in the second half of 2025 [5] - Service revenue from data collaborations was approximately $890,000 in Q4 2025 [17] - Revenue from DIXI Medical was about $3 million, a 4% decline compared to Q4 2024, as the commercial partnership ended [17] Market Data and Key Metrics Changes - The majority of growth is coming from Level 4 centers, indicating increased adoption and utilization of the RNS System [5] - The company is expanding access to RNS therapy through community pathways and referral networks [5] Company Strategy and Development Direction - NeuroPace is focused on deepening adoption within the adult focal epilepsy indication while preparing for future indication expansions [5][8] - The company is investing in its commercial organization, including sales representative additions and nurse navigator resources [8] - The submission of a PMA supplement to the FDA for an expanded indication in idiopathic generalized epilepsy (IGE) is a key strategic move [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a minimum of 20% growth in the core RNS business for 2026 [6] - The company reiterated its 2026 revenue guidance of $98 million to $100 million, assuming 20%-22% growth in the core RNS business [7][26] - Management highlighted the importance of ongoing investments in commercial activities and product development to drive future growth [31] Other Important Information - The company achieved its second consecutive quarter of positive adjusted EBITDA and positive cash generation in Q4 2025 [7][22] - NeuroPace is advancing its product pipeline, including AI tools designed to enhance physician workflow and patient outcomes [10][12] Q&A Session Summary Question: How quickly can the company translate from IGE approval to revenue collection? - Management indicated that extending coverage in the private payer community is essential and that preparations are already underway [38] Question: What is the impact of pricing on RNS growth in Q4? - Management noted consistent mid-single-digit pricing increases annually, with Q4 growth primarily driven by initial implants rather than pricing changes [52][54] Question: What is the current state of capacity dynamics across implanting centers? - Management stated that there is sufficient capacity in the channel for prescribers and that nurse navigators are being employed to streamline patient flow [62][64] Question: Will SeizureID be a subscription service for physicians? - SeizureID will be included with the use of the RNS System, aimed at improving efficiency for clinicians [68][70] Question: Any updates on the pediatric NEST collaboration? - Management confirmed ongoing work with NEST to utilize real-world evidence for focal pediatric patients, with no specific submission timeline yet [82]

Summary of Haemonetics Conference Call Company Overview - **Company**: Haemonetics - **Industry**: Medical Technology (MedTech) - **Revenue**: Approaching $1.4 billion, diversified small midcap MedTech company - **Market Leadership**: Global leader in plasma apheresis with a billion-dollar addressable market [2][3] Key Financial Performance - **Fiscal Year Performance**: - High single-digit revenue growth - Operating margin expansion of over 800 basis points - Cumulative free cash flow of $600 million to $700 million - Added $3 in earnings per share over the four-year long-range plan (LRP) [3] Plasma Business Insights - **Growth**: Plasma segment grew 3% organically, 20% excluding CSL [4] - **Drivers of Growth**: - Sustained share gains - Innovation-led platform benefits - Increased collection strength [5] - **Persona PLUS Launch**: - Mid-single digit yield increase compared to Persona - Built on data-driven approach with a pivotal trial involving over 30,000 plasma donations [6][8] Customer Relationships and Market Position - **Customer Engagement**: Strong relationships leading to share gains and deeper strategic partnerships [10] - **Market Leadership**: Expectation to grow global marketplace leadership for the foreseeable future [12] Competitive Landscape - **Competitors**: Mention of Terumo's Rika and other competitors, with emphasis on Haemonetics' integrated platform and lower cost metrics [13][14] - **NexSys and Persona PLUS**: Positive reception from customers, leading to standardization around Haemonetics' technology [10] Interventional Technologies and Vascular Closure - **Challenges**: Acknowledgment of challenges in the vascular closure space but confidence in returning to above-market growth [19][20] - **Market Dynamics**: Shift to Ambulatory Surgical Centers (ASCs) and increased adoption of PFA expected to favor Haemonetics [21] - **Product Launches**: - MVP label expansion in the U.S. and Japan - Vivasure acquisition leading to the launch of PerQseal Elite [21][27] Blood Management Technologies - **Growth Potential**: Blood management technologies, particularly TEG, showing consistent double-digit growth with significant market penetration opportunities [33][34] - **Market Size**: Global Serviceable Available Market (SAM) for TEG estimated at over $400 million, with less than 50% penetration [34] Capital Deployment Strategy - **Focus on Organic Growth**: Prioritizing R&D and commercial execution for competitive advantage [43] - **Debt Management**: Addressed $300 million debt maturity using revolver, maintaining capital structure efficiency [44] - **Share Repurchases**: Attractive risk-adjusted returns at current share prices, with plans for opportunistic capital deployment [44] Margin Improvement - **Current Margins**: Operating income margin increased from 13% to 26% over the past decade, with aspirations for further improvement [48][49] - **Future Expectations**: Anticipation of continued margin expansion driven by operational improvements and product mix [49] Outlook for FY27 - **Growth Expectations**: Balanced, sustainable growth with continued revenue growth, margin expansion, and free cash flow [53] Conclusion - **Company's Position**: Haemonetics is positioned for future growth with a strong focus on innovation, customer relationships, and market leadership in plasma and blood management technologies [55]

2026 年 3 月 2 日 医药: 超配 证券研究报告 / 公司更新报告 联影医疗 (688271 CH, 买入, 目标价: RMB185.31) 2H25 经营业绩迎拐点，2026 年医疗设备行业高景气有望延续 2H25 公司经营业绩进入拐点：根据公司 2025 年业绩快报，联影医疗预计实现营业收入 138.2 亿元，同比增长 34.2%；归母净利润 18.9 亿元，同比增长 49.6%；每股收益 （EPS）为 2.29 元。我们预计 4Q25 公司实现收入和净利润 49.6 亿元和 7.7 亿元，同比 分别增长 48.2%和 30.3%。分季度看，2025 年 1-3 季度公司实现收入和净利润增速分别为 5.4%/ 18.6%/ 75.4%和 1.9%/ 7.0%/ 143.8%。根据公司业绩快报，公司 2025 年业绩增长 主要受公司创新产品持续推出、高端产品市场认可度不断提升、全球营销及服务进一步体 系完善、海外业务快速增长、管理运营质量持续优化、国内设备更新政策逐步常态化落地 等多重因素推动。 赵冰, 分析师 证书编号：S1680519040001 电话：+86 21 6015 6766 注：历史 ...

策略研究 | 证券研究报告 — 总量点评 2026 年 3 月 1 日 3 月金股组合 中银证券研究部 2026 年 3 月金股 3 月金股组合 中银国际证券股份有限公司 具备证券投资咨询业务资格 策略研究 证券分析师：王君 (8610)66229061 jun.wang@bocichina.com 证券投资咨询业务证书编号：S1300519060003 证券分析师：徐沛东 (8621)20328702 peidong.xu@bocichina.com 证券投资咨询业务证书编号：S1300518020001 策略观点：A 股短期波动中期聚焦国内主线，资源品行情正当时。美以 军事打击伊朗对于全球市场及资产价格的影响取决于行动的目标及持续 性。金价上行有望得到进一步支撑。无论是当下的中东局势还是特朗普 关税政策的反复都为短期市场增加了较高的不确定性因素。而这种不确 定性下的避险情绪将为短期贵金属价格形成有力支撑。目前来看，对于 A 股的影响更多集中在风险偏好层面，中期来看，A 股市场将会回归国内 基本面及政策预期。国内两会即将开幕，A 股短期冲击幅度或小于海外， 节后复工情况、两会前后宏观政策的释放是国内投资者关 ...

中经记者 孙汝祥 夏欣 北京报道 2026年以来，严打上市公司信息披露误导性陈述，成为证监会监管执法一个新重点。 自1月14日至2月13日，一个月之内，证监会官网接连4次通报对4家上市公司涉嫌误导性陈述立案调查。 其中，容百科技（688005.SH）在涉嫌误导性陈述5天后即被立案，不足一个月即收到《行政处罚事先 告知书》，公司及2名责任人合计将被罚款950万元。 被立案19天之后，2月6日，容百科技发布公告称收到《行政处罚事先告知书》。因重大合同公告涉嫌误 导性陈述，宁波证监局拟决定对公司给予警告，并处以450万元罚款；对董事长兼总经理白厚善、董事 会秘书俞济芸给予警告，并分别处以300万元、200万元罚款。 2026年1月13日晚，容百科技发布《关于与宁德时代签署日常经营重大合同的公告》，披露了"自2026年 第一季度开始至2031年，容百科技合计为宁德时代供应国内区域磷酸铁锂正极材料预计为305万吨，协 议总销售金额超1200亿元"等信息。 宁波证监局指出，容百科技重大合同公告披露的相关信息，未能真实、准确、完整地反映《合作协议》 实际条款内容等情况。《合作协议》并未对总销售金额作出约定，1200亿元合同 ...

DENTSPLY SIRONA logo Key Points Q4 revenue was $961 million and the company took a $144 million non‑cash goodwill/intangible impairment, while full‑year sales fell to $3.68 billion even as adjusted EBITDA margin expanded to 18.1%. Dentsply Sirona launched a 24‑month "Return‑to‑Growth" plan that increases R&D and commercial investment, includes a restructuring expected to unlock about $120 million annually, and eliminated the dividend to prioritize debt reduction and eventual share repurchases. For 2 ...

医药生物行业 10% 医药生物 沪深300 标配（维持） 医药生物行业双周报（2026/2/13-2026/2/26） 静待板块回暖 -35% -30% -25% -20% -15% -35% -30% -35% -30% -25% -20% -40% -20% 0% 20% 医药生物 沪深300 -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 2026 年 2 月 27 日 分析师：谢雄雄 SAC 执业证书编号： S0340523110002 电话：0769-22110925 邮箱： xiexiongxiong@dgzq.com.cn 医药生物（申万）指数走势 资料来源：iFind，东莞证券研究所 相关报告 ◼ SW医药生物行业跑输同期沪深300指数。2026年2月13日-2026年2月26 日，SW医药生物行业下跌0.95%，跑输同期沪深300指数约1.1个百分点。 SW医药生物行业三级细分板块中，多数细分板块均录得正收益，其中其 他生物制品和医院板块涨幅居前，分别上涨2.42%和1.80%，医疗研发外 包和线下药店板块跌幅居前，分别下跌3.80%和0.65%。 ...